Human Microbiome Market by Product (Prebiotic, Probiotic, Food, Medical Food, Drug), Application (Therapeutic), Disease (Infectious, Metabolic/Endocrine, Cancer, Blood, Neurological), Research Technology (Proteomics, Metabolomics) - Global Forecast to 2027
[128 Pages Report] The global human microbiome market is projected to reach USD 1,731 million in 2027 from USD 942 million in 2024, at CAGR of 22.5 % during the forecast period. Market growth is largely driven by the increasing focus on the development of human microbiome therapy. It has also become a validated target for drug development. The growing number of collaborations between market players is expected to offer a wide range of growth opportunities for market players during the forecast period. However, a lack of expertise and detailed research on the human microbiome is restraining the growth of this market.
The therapeutics segment to account for the largest share of the human microbiome market in 2022.
Based on application, the market is segmented into therapeutics and diagnostics. The therapeutics segment to account for the largest share of the market in 2022. The increase in funding for R&D into microbiome-based therapies worldwide is the major factor driving the growth of this application segment. In addition, technological advancements, the increasing number of clinical trials for the diagnostics segment, and growing collaborations between key market players and research institutes are also supporting market growth.
By disease, the infectious diseases segment is expected to grow at the highest CAGR during the forecast period.
Based on disease, the human microbiome market is segmented into infectious diseases, endocrine & metabolic disorders, inflammatory diseases, cancer, and other diseases. The infectious disease segment is expected to register the highest growth rate during the forecast period. Increasing cognizance of the ill-effects of antibiotic use on the natural flora (such as disruptions) has highlighted the need for specific bacterial-targeted therapy for infectious diseases. The rising incidence of infections due to microbial dysbiosis, as a result of antibiotic treatment, and the increasing number of clinical trials for the development of target-specific microbiome-based therapies are the major factors driving the growth of this segment.
By technology, the genomics segment is expected to grow at the highest CAGR during the forecast period.
On the basis of technology, the human microbiome research spending market is segmented into genomics, proteomics, and metabolomics. The genomics segment is expected to register the highest CAGR during the forecast period. The increasing number of projects funded by private and government bodies is a key driver for the genomics market.
The market in North America is expected to grow at the highest CAGR during the forecast period.
The market in North America is estimated to grow at the highest CAGR during the forecast period. Factors such as the increasing incidence of lifestyle diseases, rising awareness on preventive healthcare, availability of funding for microbiome research, and growing acceptance of probiotic products are the factors driving the North American market.
Key Market Players
The major companies in the human microbiome market include Enterome Bioscience (France), Seres Therapeutics (US), and 4D Pharma (UK).
Enterome Bioscience (France) was one of the major players operating in the market in 2018. The company is a clinical-stage biopharmaceutical firm focused on the development of innovative therapies to treat microbiome-associated diseases with a focus on IBDs, Crohn’s, and cancer (glioblastoma, colon, pancreatic, lung, and breast) indications. In 2018, the company raised USD 38.5 million (EUR 32 million) in a Series D financing, which will be used for clinical trials of Enterome’s lead development programs, namely, Phase 2 study of the company’s oral FimH blocker EB8018 for the treatment of Crohn’s disease and Phase 1b study of EO2315, a novel immuno-oncology candidate, in patients with aggressive brain cancer (glioblastoma multiforme). Moreover, the company received a loan facility of USD 44.3 million (EUR 40 million) from the European Investment Bank (EIB) to support the acceleration of its pipeline and technology development. Such financing will help the company to conduct research on its microbiome-based products.
Scope of the Report
|
Report Metric |
Details |
|
Market size available for years |
2018–2027 |
|
Base year considered |
2018 |
|
Forecast period |
2019–2027 |
|
Forecast units |
Values (USD Million) |
|
Segments covered |
Human Microbime Market—Product, Disease, Application, and Region |
|
Segments covered |
Human Microbiome Research Spending Market— Technology |
|
Geographies covered |
North America (US & Canada), Europe, APAC, and RoW |
|
Companies covered |
Enterome Bioscience (Europe), Seres Therapeutics (US), Pharma PLC (UK), UBiome (US), E.I. du Pont de Nemours and Company (DuPont) (US), Synlogic (US), Second Genome (US), Vedanta Biosciences (US), Ferring Pharmaceuticals (Switzerland), Evelo Biosciences (US), ViThera Pharmaceuticals (US), BiomX (Israel), and LNC Therapeutics (France) |
Based on product, the human microbiome market is segmented as follows:
- Probiotics
- Prebiotics
- Foods
- Medical Foods
- Diagnostic Tests
- Drugs
Based on disease, the human microbiome market is segmented as follows:
- Infectious Diseases
- Endocrine and Metabolic Disorders
- Inflammatory Diseases
- Cancer
- Other Diseases (Cardiovascular Disease, Neurological Disorders, Irritable Bowel Syndrome, and Hematological Disorders)
Based on application, the human microbiome market is segmented as follows:
- Therapeutics
- Diagnostics
Based on the technology, the human microbiome research spending market is segmented as follows:
- Genomics
- Sequencing
- Other Genomic Technologies (Polymerase Chain Reaction (PCR), Fluorescence In Situ Hybridization (FISH), and DNA Microarrays)
- Proteomics
- Metabolomics
Based on region, the human microbiome market is segmented as follows:
- North America
- US
- Canada
- Europe
- Asia Pacific
- Rest of the World (RoW)
Recent Developments:
- In 2019, Seres collaborated with AstraZeneca to get a better understanding of the microbiome in augmenting the efficacy of cancer immunotherapy, including potential synergy with AstraZeneca compounds.
- In 2018, Enterome entered into a co-development and co-promotion agreement with Takeda for its investigational drug candidate EB8018. This drug is used in patients with Crohn's disease and has the potential to expand its use to other gastrointestinal (GI) disorders and liver diseases.
- In 2016, 4D Pharma acquired the production assets of Instituto Biomar to expand its clinical and production capabilities of live biotherapeutics.
Key questions addressed by the report:
- Who are the major market players in the human microbiome market?
- What are the regional growth trends and the largest revenue-generating regions for the market?
- What are the major drivers and challenges in the market?
- What are the major product segments in the market?
- What are the major technologies used in the human microbiome research spending market?
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
Table of Contents
1 Introduction (Page No. - 15)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Covered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders
2 Research Methodology (Page No. - 19)
2.1 Research Data
2.1.1 Secondary Sources
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Sources
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Key Industry Insights
2.2 Market Size Estimation
2.3 Market Breakdown and Data Triangulation
3 Executive Summary (Page No. - 25)
4 Premium Insights (Page No. - 28)
4.1 Human Microbiome: Market Overview
4.2 Human Microbiome Market, By Product
4.3 Europe: Market, By Product & Application (2022)
4.4 Market, By Disease
5 Market Overview (Page No. - 32)
5.1 Market Dynamics
5.1.1 Drivers
5.1.1.1 Increased Focus on Human Microbiome Therapy Development
5.1.1.2 Human Microbiome as A Validated Target for Drug Development
5.1.1.3 Human Microbiome for Early Disease Detection and Diagnosis
5.1.2 Restraints
5.1.2.1 Lack of Expertise and Detailed Research
5.1.2.2 Barriers in Proving the Causal Link Between Dysbiosis and Disease
5.1.3 Opportunities
5.1.3.1 Investigational New Drug Requirements for Fecal Microbiota
5.1.3.2 Increasing Collaborations
5.1.4 Challenges
5.1.4.1 Government Regulations
6 Human Microbiome Market, By Product (Page No. - 37)
6.1 Introduction
6.2 Probiotics
6.2.1 Ongoing Researches on Probiotics Promoting Its Credibility in Health Claims and Safety
6.3 Prebiotics
6.3.1 Development of Targeted Prebiotics Towards Enhancing GUT Microbiota is the Key Growth Driver for This Segment
6.4 Foods
6.4.1 Rising Awareness of Microbiota-Targeted Diets is Driving Market Growth
6.5 Medical Foods
6.5.1 Usage of Targeted Microbiome for Treating Metabolic Syndrome is Expected to Drive This Segment
6.6 Diagnostic Tests
6.6.1 Increased Consumer Awareness About Microbiome-Based Tests, Which Provide Preventative Health Insights to Drive This Segment
6.7 Drugs
6.7.1 Increasing Number of Microbiome-Based Drug Pipeline is the Key Factor Driving the Growth of This Segment
7 Human Microbiome Market, By Application (Page No. - 47)
7.1 Introduction
7.2 Therapeutics
7.2.1 Availability of Funding for Research and Growing Evidence for Effectiveness of Microbiome is Favoring Market Growth
7.3 Diagnostics
7.3.1 Increasing Focus of Biotech Companies on Life Science Research is Supporting Market Growth
8 Human Microbiome Market, By Disease (Page No. - 52)
8.1 Introduction
8.2 Infectious Diseases
8.2.1 Increasing R&D Into Targeted Anti-Bacterial Products Will Drive Market Growth
8.3 Inflammatory Diseases
8.3.1 Side-Effects of Immunosuppressants have Prompted Demand for Better Therapeutics
8.4 Endocrine & Metabolic Disorders
8.4.1 GUT Microbiota has Become A Potential Nutritional and Pharmacological Target for Obesity Management
8.5 Cancer
8.5.1 Microbiome-Based Products have Demonstrated Efficacy in the Treatment of Cancer Polyps
8.6 Other Diseases
9 Human Microbiome Research Spending Market, By Technology (Page No. - 62)
9.1 Introduction
9.2 Genomics
9.2.1 Sequencing
9.2.1.1 The Declining Cost of Next-Generation Sequencing is Driving the Growth of This Market
9.2.2 Other Genomics Technologies
9.3 Proteomics
9.3.1 Technological Advancements in Proteomics Technologies to Drive Market Growth
9.4 Metabolomics
9.4.1 Metabolomics has Several Advantages Over Genomics and Proteomics in Microbiome Research
10 Human Microbiome Market, By Region (Page No. - 70)
10.1 Introduction
10.2 Europe
10.2.1 Extended Applications for Microbiome to Therapeutic Areas to Boost the Adoption of Microbiome-Based Products in Europe
10.3 North America
10.3.1 US
10.3.1.1 Rising of Investment By Nih to Support Microbiome Research is Driving the Market Growth in the US
10.3.2 Canada
10.3.2.1 The Canadian Microbiome Initiative 2 is Supporting the Market Growth in the Country
10.4 Asia Pacific
10.4.1 Increasing Focus on Microbiome Research to Drive Market Growth
10.5 Rest of the World (RoW)
10.5.1 Increasing Incidence of Cancer to Drive the Development of Microbiome-Based Diagnostic Tools in RoW
11 Competitive Landscape (Page No. - 92)
11.1 Overview
11.2 Competitive Leadership Mapping (2018)
11.2.1 Innovators
11.2.2 Emerging Companies
11.3 Competitive Situation and Trends
11.3.1 Agreements, Collaborations, and Partnerships
11.3.2 Acquisitions and Mergers
11.3.3 Product Launches
11.3.4 Expansions
12 Company Profiles (Page No. - 97)
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*
12.1 Enterome Bioscience
12.2 Seres Therapeutics
12.3 4D Pharma PLC
12.4 Ubiome, Inc.
12.5 E.I. Du Pont De Nemours and Company
12.6 Synlogic
12.7 Second Genome
12.8 Vedanta Biosciences, Inc.
12.9 Ferring Pharmaceuticals
12.10 Evelo Biosciences, Inc.
12.11 Vithera Pharmaceuticals, Inc.
12.12 Biomx
12.13 LNC Therapeutics
*Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View Might Not Be Captured in Case of Unlisted Companies.
13 Appendix (Page No. - 122)
13.1 Discussion Guide
13.2 Knowledge Store: Marketsandmarkets’ Subscription Portal
13.3 Available Customizations
13.4 Related Reports
13.5 Author Details
List of Tables (82 Tables)
Table 1 Human Microbiome Market, By Product, 2019–2027 (USD Million)
Table 2 Market for Probiotics, By Region, 2021–2027 (USD Million)
Table 3 North America: Market for Probiotics, By Country 2021–2027 (USD Million)
Table 4 Human Microbiome Market for Prebiotics, By Region, 2021–2027 (USD Million)
Table 5 North America: Prebiotics Market, By Country 2021–2027 (USD Million)
Table 6 Market for Foods, By Region, 2021–2027 (USD Million)
Table 7 North America: Market for Foods, By Country 2021–2027 (USD Million)
Table 8 Market for Medical Foods, By Region, 2021–2027 (USD Million)
Table 9 North America: Human Microbiome Market for Medical Foods, By Country 2021–2027 (USD Million)
Table 10 Human Microbiome Market for Diagnostic Tests, By Region, 2019–2027 (USD Million)
Table 11 North America: Market for Diagnostic Tests, By Country 2019–2027 (USD Million)
Table 12 Market for Drugs, By Region, 2021–2027 (USD Million)
Table 13 North America: Market for Drugs, By Country 2021–2027 (USD Million)
Table 14 Human Microbiome Market, By Application, 2019–2027 (USD Million)
Table 15 Market for Therapeutics, By Region, 2019–2027 (USD Million)
Table 16 North America: Market for Therapeutics, By Country, 2019–2027 (USD Million)
Table 17 Human Microbiome Market for Diagnostics, By Region, 2019–2027 (USD Million)
Table 18 North America: Market for Diagnostics, By Country, 2019–2027 (USD Million)
Table 19 Market, By Disease, 2019–2027 (USD Million)
Table 20 Development of Microbiome-Based Anti-Bacterial Drugs for Infectious Diseases
Table 21 Market for Infectious Diseases, By Region, 2019–2027 (USD Million)
Table 22 North America: Human Microbiome Market for Infectious Diseases, By Country, 2019–2027 (USD Million)
Table 23 Development of Microbiome-Based Products for Inflammatory Diseases
Table 24 Market for Inflammatory Diseases, By Region, 2019–2027 (USD Million)
Table 25 North America: Human Microbiome Market for Inflammatory Diseases, By Country, 2019–2027 (USD Million)
Table 26 Development of Microbiome-Based Products for Metabolic Diseases
Table 27 Market for Endocrine & Metabolic Disorders, By Region, 2019-2027 (USD Million)
Table 28 North America: Human Microbiome Market for Endocrine & Metabolic Disorders, By Country, 2019–2027 (USD Million)
Table 29 Market for Cancer, By Region, 2019–2027 (USD Million)
Table 30 North America: Human Microbiome Market for Cancer, By Country, 2019–2027 (USD Million)
Table 31 Market for Other Diseases, By Region, 2019–2027 (USD Million)
Table 32 North America: Market for Other Diseases, By Country, 2019–2027 (USD Million)
Table 33 Human Microbiome Research Spending Market, By Technology, 2017–2024 (USD Million)
Table 34 Human Microbiome Research Spending Market for Genomics, By Region, 2017–2024 (USD Million)
Table 35 North America: Human Microbiome Research Spending Market for Genomics, By Country, 2017–2024 (USD Million)
Table 36 Human Microbiome Research Spending Market for Genomics, By Type, 2017–2024 (USD Million)
Table 37 Human Microbiome Research Spending Market for Sequencing, By Method, 2017–2024 (USD Million)
Table 38 Human Microbiome Research Spending Market for Sequencing, By Region, 2017–2024 (USD Million)
Table 39 North America: Human Microbiome Research Spending Market for Sequencing, By Country, 2017–2024 (USD Million)
Table 40 Human Microbiome Research Spending Market for Other Genomics Technologies, By Region, 2017–2024 (USD Million)
Table 41 North America: Human Microbiome Research Spending Market for Other Genomics Technologies, By Country, 2017–2024 (USD Million)
Table 42 Human Microbiome Research Spending Market for Proteomics, By Region, 2017–2024 (USD Million)
Table 43 North America: Human Microbiome Research Spending Market for Proteomics, By Country, 2017–2024 (USD Million)
Table 44 Human Microbiome Research Spending Market for Metabolomics, By Region, 2017–2024 (USD Million)
Table 45 North America: Human Microbiome Research Spending Market for Metabolomics, By Country, 2017–2024 (USD Million)
Table 46 Human Microbiome Market, By Region, 2019–2027 (USD Million)
Table 47 Human Microbiome Research Spending Market, By Region, 2017–2024 (USD Million)
Table 48 Europe: Human Microbiome Market, By Product, 2019–2027 (USD Million)
Table 49 Europe: Market, By Application, 2019–2027 (USD Million)
Table 50 Europe: Market, By Disease, 2019–2027 (USD Million)
Table 51 Europe: Human Microbiome Research Spending Market, By Technology, 2017–2024 (USD Million)
Table 52 Europe: Human Microbiome Research Spending Market for Genomics, By Type, 2017–2024 (USD Million)
Table 53 North America: Market, By Product, 2019–2027 (USD Million)
Table 54 North America: Market, By Application, 2019–2027 (USD Million)
Table 55 North America: Human Microbiome Market, By Disease, 2019–2027 (USD Million)
Table 56 North America: Human Microbiome Research Spending Market, By Technology, 2017–2024 (USD Million)
Table 57 North America: Human Microbiome Research Spending Market for Genomics, By Type, 2014–2021 (USD Million)
Table 58 US: Human Microbiome Market, By Product, 2019–2027 (USD Million)
Table 59 US: Market, By Application, 2019–2027 (USD Million)
Table 60 US: Market, By Disease, 2019–2027 (USD Million)
Table 61 US: Human Microbiome Research Spending Market, By Technology, 2017–2024 (USD Million)
Table 62 US: Human Microbiome Research Spending for Genomics, By Type, 2014–2021 (USD Million)
Table 63 Indicative List of Projects on Human Microbiome in 2018
Table 64 Canada: Market, By Product, 2019–2027 (USD Million)
Table 65 Canada: Market, By Application, 2019–2027 (USD Million)
Table 66 Canada: Human Microbiome Market, By Disease, 2019–2027 (USD Million)
Table 67 Canada: Human Microbiome Research Spending Market, By Technology, 2017–2024 (USD Million)
Table 68 Canada: Human Microbiome Research Spending Market for Genomics, By Type, 2014–2021 (USD Million)
Table 69 Asia Pacific: Human Microbiome Market, By Product, 2019–2027 (USD Million)
Table 70 Asia Pacific: Market, By Application, 2019–2027 (USD Million)
Table 71 Asia Pacific: Human Microbiome Market, By Disease, 2019–2027 (USD Million)
Table 72 Asia Pacific: Human Microbiome Research Spending Market, By Technology, 2017–2024 (USD Million)
Table 73 Asia Pacific: Human Microbiome Research Spending Market for Genomics, By Type, 2014–2021 (USD Million)
Table 74 RoW: Human Microbiome Market, By Product, 2019–2027 (USD Million)
Table 75 RoW: Market, By Application, 2019–2027 (USD Million)
Table 76 RoW: Human Microbiome Market, By Disease, 2019–2027 (USD Million)
Table 77 RoW: Human Microbiome Research Spending Market, By Technology, 2017–2024 (USD Million)
Table 78 RoW: Human Microbiome Research Spending Market for Genomics, By Type, 2014–2021 (USD Million)
Table 79 Agreements and Partnerships, 2016–2019
Table 80 Acquisitions and Mergers 2016–2019
Table 81 Product Launches, 2016–2019
Table 82 Expansions, 2016–2019
List of Figures (22 Figures)
Figure 1 Research Design
Figure 2 Primary Sources
Figure 3 Bottom-Up Approach
Figure 4 Top Down Approach
Figure 5 Data Triangulation Methodology
Figure 6 Human Microbiome Market Share, By Product, 2022
Figure 7 Market, By Application, 2022
Figure 8 Geographical Snapshot of the Human Microbiome Market
Figure 9 Increasing Focus on Human Microbiome Therapy Development to Drive the Growth of This Market
Figure 10 Probiotics Dominated the Human Microbiome Products Market in 2022
Figure 11 Infectious Diseases to Register the Highest Growth in the Market, By Disease, During the Forecast Period
Figure 12 Market: Drivers, Restraints, Opportunities, and Challenges
Figure 13 Number of Microbiome Modulators in Active Development, By Year, 2011–2017
Figure 14 Geographic Snapshot: North America to Grow at the Highest CAGR During the Forecast Period
Figure 15 Europe to Dominate the Human Microbiome Market During the Period of 2024 to 2027
Figure 16 Asia Pacific Market: Snapshot
Figure 17 Market (Global), Competitive Leadership Mapping, 2018
Figure 18 Seres Therapeutics: Company Snapshot (2018)
Figure 19 4D Pharma PLC: Company Snapshot (2018)
Figure 20 E.I. Du Pont De Nemours and Company: Company Snapshot (2018)
Figure 21 Synlogic: Company Snapshot (2018)
Figure 22 Evel0 Biosciences, Inc.: Company Snapshot (2018)
The study involved two major activities in estimating the current market size of the human microbiome market. Exhaustive research was conducted to collect information on the market as well as its peer and parent markets. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and subsegments.
Secondary Research
In the secondary research process, various sources such as directories, and databases (such as Bloomberg Business and Factiva) to identify and collect information useful for this technical, market-oriented, and commercial study of the global human microbiome market. These secondary sources include World Health Organization (WHO), Human Microbiome Project (HMP), Organisation for Economic Co-operation and Development (OECD), National Institutes of Health (NIH), Food and Drug Administration (FDA), ClinicalTrials.gov, Company Websites, Annual Reports, SEC Filings, Press Releases, Investor Presentations, Expert Interviews, and MarketsandMarkets Analysis. Secondary research was mainly used to obtain vital information about the industry’s supply chain, the total pool of key players, market classification, and segmentation according to industry trends to the bottom-most level and regional markets. It was also used to obtain information about the key developments from a market-oriented perspective.
Primary Research
Primary sources were several industry experts from core-related industries and preferred suppliers, manufacturers, distributors, service providers, reimbursement providers, technology developers, and doctors. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. Primary sources from the demand side include key opinion leaders in hospitals. The primary sources from the supply side include industry experts, such as CEOs, vice presidents, marketing directors, technology and innovation directors, and related key executives from various key companies and organizations operating in the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information.
Following is the profile breakup of primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches have been used to estimate and validate the size of the human microbiome market and to estimate the size of various submarkets. In this report, the global market size for human microbiome was calculated using the epidemiology approach.
- Key indications were identified for which microbiome therapy clinical trials are underway
- The therapy market pertaining to each indication was derived based on secondary and primary research
- Microbiome therapeutics are likely to be adopted by a set of patients who show side-effects for existing therapies. Therefore, the percentage of the patient population showing some side-effects with existing therapies were identified. This percentage was then applied to the total therapy market to derive the total addressable market for human microbiome.
- To calculate the total market for microbiome therapy, the adoption rate for microbiome therapies was applied to the total addressable market
- This approach was then validated from primary experts from both demand and supply-side
Individual shares of each product, disease, region, and application were arrived based on parameters such as product pipeline, clinical trials progress, target indications, funding scenario, and research intensity in microbiome.
After arriving at the overall market size—using the market size estimation processes explained above—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides of the human microbiome market.
Report Objectives
- To define, describe, segment, and forecast the market on the basis of product, application, disease, technology, and region
- To define, describe, segment, and forecast the human microbiome research spending market on the basis of technology
- To provide detailed information about the factors influencing market growth (drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of market segments with respect to four main regions (along with countries), namely, North America, Europe, the Asia Pacific (APAC), and the Rest of the World (RoW)
- To profile key players and comprehensively analyze their core competencies in terms of key developments, product portfolios, and financials
- To track and analyze competitive developments such as acquisitions; partnerships, agreements, & collaborations; product launches; and expansions in the human microbiome market
Get in-depth analysis of the COVID-19 impact on the Human Microbiome Market
Benchmarking the rapid strategy shifts of the Top 100 companies in the Human Microbiome Market
Request For Special Pricing
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Human Microbiome Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Growth opportunities and latent adjacency in Human Microbiome Market